Sure, it's neutral however based on the stocks reaction today it looks like some folks were hoping the trial would have met it's end point at the second look. However, the P3 pts were disease stable at time of enrollment so the fact that the trial wasn't stopped at the 2nd interim really isn't all that surprising.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.